Details of Disease

General Information of Disease (ID: DISY8WGS)

• Disease Name: Staphylococcus infection
• Synonyms: staphylococcal infection
• Disease Class: 1B5Y: Staphylococcal/streptococcal disease
• Definition: An infection caused by Staphylococcus.
• Disease Hierarchy:
  DIS5QJ9S: Bacterial infection
  DISEM33Q: Infectious disease
  DISY8WGS: Staphylococcus infection
• ICD Code:
  ICD-11: ICD-11: 1B5Y
  ICD-10: ICD-10: A49.0
  ICD-9: ICD-9: 001-139
  Expand ICD-11: '1C41
  Expand ICD-10: 'A49.0
  Expand ICD-9: 001,002,003,004,005,006,007,008,009,010,011,012,013,014,015,016,017,018,019,020,021,022,023,024,025,026,027,028,029,030,031,032,033,034,035,036,037,038,039,040,041,042,043,044,045,046,047,048,049,050,051,052,053,054,055,056,057,058,059,060,061,062,063,064,065,066,067,068,069,070,071,072,073,074,075,076,077,078,079,080,081,082,083,084,085,086,087,088,089,090,091,092,093,094,095,096,097,098,099,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139
• Disease Identifiers:
  MONDO ID: MONDO_0024313
  MESH ID: D013203
  UMLS CUI: C0038160
  MedGen ID: 52483
  SNOMED CT ID: 56038003

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Telavancin	DM58VQX	Approved	Small molecular drug	[1]

This Disease is Treated as An Indication in 17 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Aurograb	DMV93I8	Phase 3	NA	[2]
StaphVAX	DM09DKO	Phase 3	NA	[3]
Vancomycin hydrochloride	DMXJ2FG	Phase 3	NA	[4]
Staphylococcus aureus vaccine	DMRBA5F	Phase 2/3	NA	[5]
V-710	DM23ARP	Phase 2/3	Vaccine	[6]
AFN-1252	DMTFE9Y	Phase 2	Small molecular drug	[7]
Altastaph	DM1Z4MR	Phase 2	NA	[8]
Exeporfinium chloride	DMTT9VU	Phase 2	Small molecular drug	[9]
NDV-3A	DM4S5UO	Phase 2	Vaccine	[10]
PF-06290510	DMUAOFM	Phase 2	Vaccine	[11]
SAL-200	DMIWL5P	Phase 2	NA	[12]
514G3	DM129VT	Phase 1/2	Antibody	[13]
PentaStaph	DM4YCF8	Phase 1/2	NA	[14]
ALS-4	DMKM3II	Phase 1	Small molecule	[15]
GSK-2392102A	DMRQH0T	Phase 1	NA	[5]
KBSA-301	DM6KRC0	Phase 1	NA	[16]
PT1.2	DMAJJ44	Phase 1	NA	[17]

This Disease is Treated as An Indication in 7 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
SA-IGIV	DMTXFEQ	Discontinued in Phase 2	NA	[18]
Staphylococcus aureus vaccine conjugate pentavalent	DMZO5CG	Discontinued in Phase 1/2	NA	[14]
MBI-853NL	DM3CD4V	Discontinued in Phase 1	NA	[19]
CVP S aureus vaccine	DMPM9H9	Terminated	NA	[21]
MC-207252	DMI8J59	Terminated	NA	[22]
MF-5137	DM72MQP	Terminated	NA	[23]
S-34109	DMPQIUH	Terminated	NA	[24]

This Disease is Treated as An Indication in 2 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PMID25197057-Compound6e	DMOHPX4	Preclinical	Small molecular drug	[20]
Savirin	DM7NS1L	Preclinical	Small molecular drug	[20]

This Disease is Treated as An Indication in 12 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
CY-403	DM7YBW4	Investigative	NA	[25]
HT-61	DMV28TA	Investigative	NA	[25]
KBSA-302	DM2P6E5	Investigative	NA	[25]
NDV-4	DM014HL	Investigative	NA	[25]
NP16	DM51S0B	Investigative	NA	[26]
PGC-lysostaphin	DMWIMTB	Investigative	NA	[25]
R-41D	DMCYQL6	Investigative	NA	[25]
Saurestat	DMXP15Y	Investigative	NA	[25]
SEB-Humab	DMTM5EW	Investigative	NA	[25]
Staphguard	DMZ7CTX	Investigative	NA	[25]
SX5	DMA91QU	Investigative	Small molecular drug	[25]
SX8	DMC5YUH	Investigative	Small molecular drug	[25]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 5 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CD36	TTPJMCU	moderate	Biomarker	[27]
DCLK3	TTMYK4Z	Strong	Biomarker	[28]
DFFA	TTYVQ9C	Strong	Biomarker	[29]
PDE4B	TTVIAT9	Strong	Genetic Variation	[30]
RICTOR	TT143WL	Strong	Biomarker	[31]

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC9A6	DTN0JXW	Strong	Biomarker	[32]

This Disease Is Related to 6 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ACE	OTDF1964	moderate	Biomarker	[33]
DLGAP4	OTNELLIN	moderate	Biomarker	[34]
MARCHF5	OTBK6BBM	Strong	Genetic Variation	[35]
ORAI3	OTUP3OH3	Strong	Altered Expression	[36]
PANK1	OT2CZVRT	Strong	Biomarker	[37]
PIGN	OTHHTJKX	Strong	Biomarker	[38]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] ClinicalTrials.gov (NCT00217841) Aurograb and Vancomycin in MRSA Infection. U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT00211913) StaphVAX in Cardiovascular Surgery Patients. U.S. National Institutes of Health.
• [4] ClinicalTrials.gov (NCT03181932) A Study of AeroVanc for the Treatment of MRSA Infection in CF Patients. U.S. National Institutes of Health.
• [5] ClinicalTrials.gov (NCT01160172) A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Staphylococcal Investigational Vaccine in Healthy Adults. U.S. National Institutes of Health.
• [6] ClinicalTrials.gov (NCT00518687) Efficacy, Immunogenicity, and Safety of a Single Dose of V710 in Adult Patients Scheduled for Cardiothoracic Surgery (V710-003 AM2). U.S. National Institutes of Health.
• [7] Activity of AFN-1252, a novel FabI inhibitor, against Staphylococcus aureus in an in vitro pharmacodynamic model simulating human pharmacokinetics. J Chemother. 2013 Feb;25(1):32-5.
• [8] ClinicalTrials.gov (NCT00066989) Safety Study of an Intravenous Staphylococcus Aureus Immune Globulin (Human), [Altastaph] in Low-Birth-Weight-Neonates. U.S. National Institutes of Health.
• [9] ClinicalTrials.gov (NCT03915470) Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection. U.S. National Institutes of Health.
• [10] ClinicalTrials.gov (NCT03455309) Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization. U.S. National Institutes of Health.
• [11] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035724)
• [12] ClinicalTrials.gov (NCT01855048) A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of N-Rephasin SAL200 in Healthy Male Volunteers. U.S. National Institutes of Health.
• [13] ClinicalTrials.gov (NCT02357966) A Study of the Safety and Efficacy of 514G3 in Subjects Hospitalized With Bacteremia Due to Staphylococcus Aureus. U.S. National Institutes of Health.
• [14] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026041)
• [15] ClinicalTrials.gov (NCT05274802) A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of ALS-4 (IM032) Administered Orally to Healthy Volunteers. U.S.National Institutes of Health.
• [16] ClinicalTrials.gov (NCT01589185) Safety, Pharmacokinetics and Efficacy of KBSA301 in Severe Pneumonia (S. Aureus). U.S. National Institutes of Health.
• [17] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029592)
• [18] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012879)
• [19] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013410)
• [20] Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance. Nat Rev Drug Discov. 2017 Jul;16(7):457-471.
• [21] Chimeric plant virus particles administered nasally or orally induce systemic and mucosal immune responses in mice. J Virol. 1999 Feb;73(2):930-8.
• [22] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006605)
• [23] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004011)
• [24] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007670)
• [25] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [26] Dehydrosqualene Desaturase as a Novel Target for Anti-Virulence Therapy against Staphylococcus aureus.MBio. 2017 Sep 5;8(5). pii: e01224-17.
• [27] CD36 is a sensor of diacylglycerides.Nature. 2005 Feb 3;433(7025):523-7. doi: 10.1038/nature03253.
• [28] Bovine Staphylococcus aureus: Subtyping, evolution, and zoonotic transfer.J Dairy Sci. 2016 Jan;99(1):515-28. doi: 10.3168/jds.2015-9589. Epub 2015 Nov 18.
• [29] Detection of icaA, icaD genes and biofilm production by Staphylococcus aureus and Staphylococcus epidermidis isolated from urinary tract catheterized patients.J Infect Dev Ctries. 2009 Jun 1;3(5):342-51. doi: 10.3855/jidc.241.
• [30] Genome wide association study of SNP-, gene-, and pathway-based approaches to identify genes influencing susceptibility to Staphylococcus aureus infections.Front Genet. 2014 May 9;5:125. doi: 10.3389/fgene.2014.00125. eCollection 2014.
• [31] Structure and Function of Surface Polysaccharides of Staphylococcus aureus.Curr Top Microbiol Immunol. 2017;409:57-93. doi: 10.1007/82_2015_5018.
• [32] Emerging discrepancies in conventional and molecular epidemiology of methicillin resistant Staphylococcus aureus isolated from bovine milk.Microb Pathog. 2018 Mar;116:38-43. doi: 10.1016/j.micpath.2018.01.005. Epub 2018 Jan 9.
• [33] Activity of serum angiotensin converting enzyme in septic pigs treated with intrapulmonary corticosteroid.Eur J Surg. 1994 Jan;160(1):3-7.
• [34] Antibacterial and immunomodulatory activities of insect defensins-DLP2 and DLP4 against multidrug-resistant Staphylococcus aureus.Sci Rep. 2017 Sep 21;7(1):12124. doi: 10.1038/s41598-017-10839-4.
• [35] Control of MSSA and MRSA in the United States: protocols, policies, risk adjustment and excuses.Antimicrob Resist Infect Control. 2019 Jun 19;8:103. doi: 10.1186/s13756-019-0550-2. eCollection 2019.
• [36] A calcium-redox feedback loop controls human monocyte immune responses: The role of ORAI Ca2+ channels.Sci Signal. 2016 Mar 8;9(418):ra26. doi: 10.1126/scisignal.aaf1639.
• [37] Inhibitors of pantothenate kinase: novel antibiotics for staphylococcal infections.Antimicrob Agents Chemother. 2003 Jun;47(6):2051-5. doi: 10.1128/AAC.47.6.2051-2055.2003.
• [38] IgA-dominant extracapillary proliferative glomerulonephritis following Escherichia coli sepsis in a renal transplant recipient.Transpl Infect Dis. 2018 Oct;20(5):e12927. doi: 10.1111/tid.12927. Epub 2018 Jun 15.